Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7036 to 7050 of 7689 results

  1. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued [GID-TA10334]

    Technology appraisal guidance
    Discontinued

  2. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued [GID-TA10616]

    Technology appraisal guidance
    Discontinued

  3. Non-invasive skin closure devices for surgical incisions (MT775)

    In development [GID-MT593] Expected publication date: TBC

    Medical technologies guidance
    In development

  4. Surgical vessel sealing systems (MT798)

    In development [GID-MT594] Expected publication date: TBC

    Medical technologies guidance
    In development

  5. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development [GID-HST10020] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  6. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued [GID-TA10490]

    Technology appraisal guidance
    Discontinued

  7. Haemochromatosis

    Discontinued [GID-NG10287]

    NICE guideline
    Discontinued

  8. Acute bowel obstruction

    Discontinued [GID-NG10377]

    NICE guideline
    Discontinued

  9. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued [GID-NG10385]

    NICE guideline
    Discontinued

  10. Breathlessness

    Discontinued [GID-NG10387]

    NICE guideline
    Discontinued

  11. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued [GID-NG10300]

    NICE guideline
    Discontinued

  12. Atopic Dermatitis (Eczema)

    Discontinued [GID-NG10289]

    NICE guideline
    Discontinued

  13. Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]

    In development [GID-TA10391] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Surgical site infections: prevention and treatment - Update

    Discontinued [GID-NG10374]

    NICE guideline
    Discontinued

  15. Type 2 diabetes in adults: management - insulin therapy

    Discontinued [GID-NG10375]

    NICE guideline
    Discontinued